Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201
20 avr. 2022 09h30 HE
|
Atossa Therapeutics, Inc.
NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION PULMONARY DISEASE SEATTLE, April 20, 2022 (GLOBE...